Grifols, S.A. (NASDAQ:GRFS)

CAPS Rating: 3 out of 5

Results 1 - 2 of 2

Recs

0
Member Avatar GiantMonster (< 20) Submitted: 4/29/2013 11:37:38 AM : Outperform Start Price: $30.18 GRFS Score: -11.41

strong player in a consolidated market with growing demand

Recs

0
Member Avatar jspirz (< 20) Submitted: 2/26/2013 2:12:45 PM : Outperform Start Price: $28.08 GRFS Score: -10.67

Still realizing their potential after acquiring Talecris. Now a major player in the human plasma protein based therapy's.

Results 1 - 2 of 2

Featured Broker Partners


Advertisement